Axtria Highlights AI Adoption Gap in Pharma Forecasting With New Webinar

According to a recent LinkedIn post from Axtria, internal research suggests that 82% of pharmaceutical organizations have not yet applied artificial intelligence to any core forecasting assumptions, despite AI ranking as a top priority for forecasting teams. The post points to an upcoming Ignite webinar that aims to explore barriers to adoption and identify practical use cases in life sciences forecasting.

The post indicates that Axtria will draw on findings from its 2026 Life Sciences Forecasting Benchmarking Report as well as practitioner perspectives to examine where AI can add value without requiring complete workflow redesigns. Discussion topics are described as including practical generative AI entry points for current forecasting environments and the organizational requirements to scale these approaches.

Speakers are listed as Jeff Olive, Forecasting Head & Principal at Axtria, and Eric Haskel, Business Planning & Capabilities Director at AstraZeneca, signaling collaboration between a technology and analytics provider and a large biopharma player. The webinar is positioned as targeting decision makers in pharma forecasting and business planning, with a registration link provided for interested participants.

For investors, the focus on AI adoption gaps in core forecasting functions may highlight a multi-year opportunity for analytics and software vendors serving the life sciences sector. If Axtria can leverage benchmarking data and practitioner-focused content to convert interest into consulting or platform engagements, this could support incremental revenue growth and deepen relationships with larger pharma clients.

The emphasis on generative AI and practical implementation pathways may also position Axtria as an early mover in operationalizing AI for forecasting rather than treating it as a proof-of-concept capability. This could enhance the company’s competitive positioning versus other life sciences analytics providers and potentially increase switching costs for clients that standardize forecasting processes on Axtria’s methodologies and tools.

Collaboration with a senior leader from AstraZeneca in a public educational format may further underscore Axtria’s access to high-profile industry stakeholders, which can be relevant to business development and partnership prospects. While the post itself is promotional in nature, it suggests ongoing investment in thought leadership and benchmark-based insights that could support Axtria’s brand and pricing power in the specialized pharma analytics market.